Journal of Clinical Oncology
Articles in this Issue
Mapping the burden of uterine cancer in the EU from 1990-2021: Global and national disparities, age trends, and implications for public health.
e17639 Background: Uterine cancer (UC), predominantly endometrial carcinoma, is a major public health concern in the European Union (EU), driven by factor...
Real-life use of G-CSF in non-small cell lung cancer (NSCLC): Secondary data analysis from the French national cohorts KBP-ESCAP-2020-CPHG.
e24119 Background: Febrile neutropenia (FN) is a frequent related side-effect in the treatment of lung cancer (LC), a common and potentially life-threaten...
How low do you need to go? Association between various prostate-specific antigen (PSA) response measures and clinical outcomes in metastatic castration-sensitive prostate cancer (mCSPC) in the Veteran Health Administration (VHA) data.
5092 Background: Clinical trials show that combined treatment (tx) with androgen deprivation therapy (ADT) and androgen re...
Constructing genetic-immune prognostic subtypes of primary duodenal adenocarcinoma through whole exome sequencing and AI-assisted immune microenvironment analysis.
4197 Background: Primary duodenal adenocarcinoma (DA) is a rare gastrointestinal tumor with a poor prognosis. This study aimed to investigate the tumor im...
Assessment of ctDNA somatic homologous recombination deficiency (HRD) in triple-negative breast cancer (TNBC) from SWOG S1416 trial.
1012 Background: HRD is observed in up to two-thirds of g BRCA- wildtype TNBC. S1416 (NCT02595905) showed that addition of a PARP...
Dissecting primary endocrine resistance through ctDNA profiling of a hybrid real-world and clinical trial dataset in hormone receptor-positive, HER2-negative (HR+/HER2-) metastatic breast cancer (MBC).
1047 Background: New targeted therapies, including novel endocrine agents and antibody drug conjugates, are revolutionizing the treatment of HR+/HER2- met...
Observation or adjuvant therapy: The optimal regime for patients undergoing neoadjuvant chemoradiotherapy with postoperative yield pathological stage I.
e15590 Background: Neoadjuvant chemoradiotherapy (nCRT) has been leveraged in locally advanced rectal cancer (LARC) treatment before surgery, contributing...
Assessment of subtype prevalence and the impact of HER2-directed therapy on emergency department (ED) utilization by real-world breast cancer patients.
e24095 Background: Breast cancer is the most common malignant disease in women and subtype is a key prognostic factor. In HER2-positive disease, HER2-dire...
Real-world evidence of PARPi-related MDS/AML risk in breast cancer patients: An international collaborative network analysis.
535 Background: Poly (ADP-ribose) polymerase (PARP) inhibitors have emerged as a significant therapeutic advance in breast cancer treatment. However, conc...
A phase 2 study of the olaparib and AZD6738, an ATM/ATR inhibitor, in isocitrate dehydrogenase (IDH) mutant solid tumors.
3089 Background: Pre-clinical data has shown that mutations in isocitrate dehydrogenase (IDH) 1 and 2 can lead to impaired homologous recombination repair...
Impact of pregnancy history and recency of childbirth on long-term outcomes in young patients with early-stage breast cancer.
e12562 Background: Previous research has suggested that breast cancer (BC) diagnosed during pregnancy or the postpartum period exhibits more aggressive cl...
A phase I/II study of the safety and efficacy of intraperitoneal IMNN-001 in combination with neoadjuvant chemotherapy (NACT) of paclitaxel and carboplatin in patients newly diagnosed with advanced epithelial ovarian cancer (EOC): Updated survival analysis from OVATION-2 trial.
5516 Background: OVATION-2 (NCT03393884) is a randomized, controlled phase I/II study evaluating IMNN-001 in newly diagnosed advanced epithelial ovarian c...
A prospective study of whole-body MRI (WBMRI) as part of a multimodality screening program for individuals with Li-Fraumeni syndrome (LFS).
10501 Background: Individuals with LFS are at risk for developing cancer in multiple organs and therefore require a multimodal cancer screening program. W...
Impact of lymph node characteristics on clinical outcomes in clinical N2 non-small cell lung cancer patients treated with chemoradiotherapy: Single- vs. multiple-stations, bulky vs. non-bulky and discrete vs. infiltrative.
8051 Background: Stage III, N2 non-small cell lung cancer (NSCLC) is a heterogeneous disease with various patterns of lymph node metastasis. Recently, che...
Induction chemotherapy (IC) followed by concomitant radiotherapy and weekly cisplatin (CCRT) versus CCRT alone in patients with locally advanced (LA) nasopharyngeal carcinoma (NPC): Twenty-year follow-up of a randomized phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation.
6088 Background: Non-endemic NPC is associated with inferior outcomes compared to the endemic form. HeCOG conducted a randomized phase II study to compare...
Oncologists’ perspectives on challenges using chemotherapy, immune checkpoint inhibitors, and targeted kinase inhibitors for metastatic cancer.
1548 Background: Compared to cytotoxic chemotherapies, the standard of care for metastatic cancers for decades, use of immune checkpoint inhibitors (ICI)...
First-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in clinically aggressive hormone receptor (HR)+/HER2− advanced breast cancer (ABC): A subgroup analysis of patients (pts) with or without liver metastases (mets) from RIGHT Choice.
1069 Background: The phase II RIGHT Choice trial reported a statistically significant progression-free survival (PFS) bene...
Lung cancer enrollment of demographic subgroups in US clinical trial sites.
8095 Background: Most clinical trials globally are not representative of a diverse patient population and 78% of trial participants remain White. This may...
Multicenter phase II study of anlotinib and toripalimab in patients with advanced soft tissue sarcoma (STS) and bone sarcoma (BS).
11556 Background: This multicenter phase II study aims to evaluate the efficacy and safety of anlotinib combined with toripalimab in the treatment of pati...
TT125-802, a highly selective, well-tolerated bromodomain inhibitor of CBP/p300 with anti-tumor activity in patients with advanced solid tumors: An update on the ongoing phase I study.
e15105 Background: Transcriptional mechanisms of resistance undermine the long-term efficacy of targeted cancer therapies. TT125-802 is a small molecule t...
PROMIS scores of cancer survivors in the Comprehensive Outcomes for After Cancer Health (COACH) study: An interim analysis.
e23182 Background: The Comprehensive Outcomes for After Cancer Health (COACH) Study (NCT05349227) evaluates feasibility of a digital health coaching (DHC)...
Preliminary results from the randomized phase 2 study (1801 part 3B) of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) versus GnP alone in patients (pts) with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).
4006 Background: Elraglusib (9-ING-41) is a first-in-class inhibitor of GSK-3ß, which may mediate drug resistance, EMT, and damaged DNA and tumor immune r...
Does early recognition and treatment of immune-related myositis and myasthenia gravis reduce mortality of immune-related myocarditis?
12025 Background: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. However, some immune-related adverse events (irAEs) can be sev...
Setting a precedent: Development of a core outcome set for locoregional treatment outcome reporting in neoadjuvant breast cancer trials.
e12570 Background: Accurate information about locoregional (LR) treatments following neoadjuvant systemic therapy (NST) for breast cancer is essential for...
Assessing comparative efficacies of camrelizumab as a single or combination therapy in patients with hepatocellular carcinoma: A systematic review and network meta-analysis.
e16284 Background: Hepatocellular carcinoma (HCC) is associated with frequent recurrences and relapse. Camrelizumab (CAM), an anti-PD-1 immune checkpoint...